Zheng B.-J.,Peking Union Medical College |
Yin Y.-P.,Reference Laboratory |
Han Y.,Peking Union Medical College |
Shi M.-Q.,Peking Union Medical College |
And 5 more authors.
BMC Public Health | Year: 2014
Background: Although Mycoplasma genitalium (MG) is a common sexually transmitted infection (STI), very little information regarding the prevalence of MG among MSM (men who have sex with men) is available in China. The objective of this study was to determine the prevalence of MG among MSM in the city of Shenzhen, Guangdong Province, China, and to identify the potential risk factors associated with MG infection in this population. Methods. Between January and May 2010, a total of 409 MSM were recruited in Shenzhen, Guangdong Province, China. An anonymous questionnaire was used to collect information regarding their sociological and sexual behaviors. In addition, their first-void urine (FVU) samples and rectal swabs were collected for PCR-based MG testing. Results: Among the 406 FVU and 405 rectal swab samples were collected from 409 MSM, the overall MG prevalence was 8.1% (33/406, 95% CI 5.7%-10.6%), with a FVU positivity of 3.4% (95% CI 1.7%-5.4%) and a rectal positivity of 5.4% (95% CI 3.5%-7.7%). Using both univariate and multivariable logistic regression analyses, urethral MG infection was significantly associated with having more heterosexual behaviors (AOR 7.16, 95% CI 1.89-27.13), and with having unprotected anal intercourse in the past six months (AOR 4.80, 95% CI 1.40-16.47). Rectal MG infection was significantly associated with HIV infection based on univariate logistic regression analysis (OR = 4.49, 95% CI 1.18-17.12). Conclusions: In this study, we investigated the prevalence of MG infection in the population of interest, as determined from both urethral and rectal specimen. We showed that MG was more prevalent in MSM who had bisexual behaviors compared to those who engaged only in homosexual behaviors. Further work is needed to establish the mode of MG transmission and to identify its role in HIV transmission. Meanwhile, more attention should be paid to MG infection among MSMs, and especially bisexual MSMs, which might have critical implications for effective HIV/STD control in China. © 2014 Zheng et al.; licensee BioMed Central Ltd.
Peterson S.W.,Public Health Agency of Canada |
Martin I.,Public Health Agency of Canada |
Demczuk W.,Public Health Agency of Canada |
Bharat A.,Public Health Agency of Canada |
And 10 more authors.
Journal of Clinical Microbiology | Year: 2015
The incidence of antimicrobial-resistant Neisseria gonorrhoeae continues to rise in Canada; however, antimicrobial resistance data are lacking for approximately 70% of gonorrhea infections that are diagnosed directly from clinical specimens by nucleic acid amplification tests (NAATs). We developed a molecular assay for surveillance use to detect mutations in genes associated with decreased susceptibility to cephalosporins that can be applied to both culture isolates and clinical samples. Real-time PCR assays were developed to detect single nucleotide polymorphisms (SNPs) in ponA, mtrR, penA, porB, and one N. gonorrhoeaespecific marker (porA). We tested the real-time PCR assay with 252 gonococcal isolates, 50 nongonococcal isolates, 24 N. gonorrhoeae-negative NAAT specimens, and 34 N. gonorrhoeae-positive NAAT specimens. Twenty-four of the N. gonorrhoeae-positive NAAT specimens had matched culture isolates. Assay results were confirmed by comparison with whole-genome sequencing data. For 252 N. gonorrhoeae strains, the agreement between the DNA sequence and real-time PCR was 100% for porA, ponA, and penA, 99.6% for mtrR, and 95.2% for porB. The presence of ≥2 SNPs correlated with decreased susceptibility to ceftriaxone (sensitivities of >98%) and cefixime (sensitivities of >96%). Of 24 NAAT specimens with matched cultures, the agreement between the DNA sequence and real-time PCR was 100% for porB, 95.8% for ponA and mtrR, and 91.7% for penA. We demonstrated the utility of a real-time PCR assay for sensitive detection of known markers for the decreased susceptibility to cephalosporins in N. gonorrhoeae. Preliminary results with clinical NAAT specimens were also promising, as they correlated well with bacterial culture results. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Gupta N.,Reference Laboratory
Journal of Clinical and Diagnostic Research | Year: 2013
Hemangiomas of the pericardium are very rare primary pericardial tumours. Very few cases of pericardial hemangioma have been reported in the literature till date. We are reporting a case of a 40 years old male who presented with the complaints of chest discomfort and palpitation on exertion, of 3 months duration. ECHO and Colour Doppler ECHO which were done, revealed a large heterogeneous mass which measured 7.6 × 7.1cms, which was possibly attached to the roof and the anterior surface of the left atria, which was possibly a myxoma. Based on the radiological findings, a diagnosis of left atrial myxoma was considered. However, intra operatively, an encapsulated mass was seen within the pericardium, which was successfully excised and sent for histopathology. The histopathological examination revealed an intrapericardial hemangioma. This case has been reported on account of its extreme rarity.
Abstract: Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events. The International Liver Congress 2016 (ILC 2016) - The Annual Meeting of the European Association for the Study of the Liver - Barcelona, Spain, April 13-17, 2016 April 14, 8:00 a.m. CEST - Zhao Xu, Ph.D., Arrowhead senior scientist, and coauthors, will deliver a poster presentation titled, "Treatment of chronically HBV-infected chimpanzees with RNA interference therapeutic ARC-520 led to potent reduction of viral mRNA, DNA and proteins without observed drug resistance" (abstract THU-213) April 14, 8:00 a.m. CEST - Man-Fung Yuen, M.D., Ph.D., chair of gastroenterology and hepatology, The University of Hong Kong, and deputy chief of service, Queen Mary Hospital department of medicine, Hong Kong, and coauthors, will deliver a poster presentation titled, "Differential reductions in viral antigens expressed from cccDNA vs integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520" (abstract THU-193) April 15, 8:00 a.m. CEST - Renae Walsh, Ph.D., senior scientist, Victorian Infectious Diseases Reference Laboratory, and coauthors, will deliver a poster presentation titled, "Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis" (abstract FRI-144) American Association for Cancer Research Annual Meeting 2016 (AACR16) - New Orleans, April 16-20, 2016 April 18, 1:00 p.m. CDT - So Wong, Ph.D., Arrowhead director of oncology, and coauthors, will deliver a poster presentation titled, "Novel HIF-2α targeted RNAi therapeutic for renal cell carcinoma" (abstract 2064) Copies of presentation materials can be accessed by visiting the Events section of the company's website after each presentation is delivered. About ARC-520 Arrowhead's RNAi-based candidate ARC-520 is being investigated in the treatment of chronic HBV infection. The small interfering RNAs (siRNAs) in ARC-520 intervene at the mRNA level, upstream of the reverse transcription process where current standard of care nucleotide and nucleoside analogues act. Arrowhead is investigating ARC-520 specifically to determine if it can be used to achieve a functional cure, which is an immune clearant state characterized by hepatitis B s-antigen negative serum with or without seroconversion. Approximately 350-400 million people worldwide are chronically infected with the hepatitis B virus, which can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers globally. Arrowhead is currently conducting Phase 2b multiple dose and combination studies in chronic HBV patients. In clinical studies to date, the most common reported adverse events in all subjects completing treatment were upper respiratory infection and headache. About Arrowhead Research Corporation Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic diseases, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma. For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit ir.arrowheadresearch.com/alerts.cfm. Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Research Corporation. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
After DNA extraction, samples are prepared for the determination of GMO. © EU The JRC has published a new database, JRC GMO-Amplicons, which contains more than 240 000 DNA sequences appearing in genetically modified organisms (GMOs). It will help to verify the presence of GMOs in food, feed and environment. To date, this new database is the largest and most comprehensive in this area and could be key to developing new methods for detecting GMOs in food and feed. The number of genetically modified (GM) crops, their complexity and the related cultivation area are steadily increasing worldwide. In the EU, only one variety of maize (corn) is currently grown commercially but GM varieties of maize, cotton, soybean, oilseed rape and sugar beet are authorised for import into the EU for food and feed uses. The authorisation is granted for new products if they do not pose threats to human or animal health or to the environment. According to EU Regulation on labelling, labels have to specify if the product contains GMOs. Correct labelling requires methods for GMO detection, identification and quantification and allows consumers to make informed decisions. These methods detect one or more short DNA sequences (amplicons) characteristic of the GMO genomes, i.e. they are able to detect if GMOs are present in the product. The new JRC GMO-Amplicons database was compiled by collecting information from a large number of publicly available databanks through an automatic computer-based procedure, called "Bioinformatics pipeline", developed by the JRC experts. The database provides information on amplicons present in GMOs that are authorised in the EU and also those described either in a publication, patent, or public database (even if not authorised). This makes JRC GMO-Amplicons the most comprehensive source for the detection of DNA target sequences currently available. The new database is easily accessible via the web and helps laboratories to identify suitable target-sequences for developing detection methods, especially for unauthorised GMOs. The reliable detection of GMOs is pivotal for the enforcement of regulations on GMO authorisation and labelling. In the context of the GMO authorisation process, the European Union Reference Laboratory for GM Food and Feed of the JRC is responsible for validating, developing and optimising methods for the detection of GMOs, and harmonising their correct application throughout the EU. It also is responsible for making tools and methods available to the control laboratories. The JRC GMO-Amplicons database is the third publicly available tool that has been developed by the JRC in the GMO field, together with the JRC GMO-Matrix and the GMOMETHODS database, a decision support tool to optimise the detection of GMOs and the EU database of reference methods for GMO analysis, respectively. They all together will contribute to make the analysis of GMOs in the food chain more efficient and cost-effective. Explore further: Scientists develop robust method for analysis of intestinal bacteria